Growth in plasma demand is a kind of no-brainer, given CSL’s life-saving therapies address conditions such as haemophlia. Demand for CSL's core immunoglobin product range is expected to remain ...

(RTTNews) - At the Annual General Meeting, Paul McKenzie, Chief Executive Officer of CSL Ltd. (CSL.AX), reaffirmed the company's financial guidance for fiscal year 2025. The company still expects ...

Shares of building envelope solutions provider Carlisle Companies (NYSE:CSL) fell 8.4% in the morning session after the company reported disappointing third-quarter earnings results. Its revenue ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell short of the market’s revenue expectations in Q3 CY2024, but sales rose 5.9% year on year to $1.33 billion. Its non-GAAP ...

The $1.25 million CSL Centenary Fellowship has enabled Dr Weeden to return from the Crick Institute in London to establish her own research laboratory at WEHI in Melbourne. She plans to identify how ...

Developed in collaboration with the Max Planck Institute for Plasma Physics specifically for the Wendelstein 7-X stellarator 1, Thales’s TH1507U gyrotron has achieved a significant milestone by ...

CSL became one of Australia’s biggest companies from the fast-growing immunoglobulin products derived from blood at the heart of its portfolio. Dr Mezzanotte said plasma products would remain ...

A persistent mystery, however, has been the structure and makeup of black hole coronas — dynamic plasma regions that are part of the flow of matter into the black holes themselves. Similar to ...

CSL (AU:CSL) has released an update. CSL Limited is hosting its 2024 Research & Development Investor Briefing, offering investors insights into the company’s latest innovations and strategic ...

Bell Potter highlights that there is a lot to like about CSL. It notes that the company holds the number one and number two positions in its three key markets. These are plasma-derived therapies ...